Cover image for Vol. 22 Issue 3

Edited By: Peter G. Kerr

Impact Factor: 1.796

ISI Journal Citation Reports © Ranking: 2015: 39/77 (Urology & Nephrology)

Online ISSN: 1440-1797

Peter's Editorial Comments

"This study provides direct evidence that the PPAR-Y agonist, rosiglitazone, can protect against the loss of podocyte foor processes and down-regulation of podocyte slit diaphragm proteins in experimental focal and segmental glomerulosclerosis. Interestlingly, rosiglitazone reduced the degree of glomerulosclerosis and proteinuria, but did not prevent the loss of WT-1+ podocytes".

Additive antifibrotic effects of pioglitazone and candesartan on experimental renal fibrosis in mice (pages 327–335)

"This paper shows that the combination of peroxisome proliferator-activated receptor -Y (PPAR-Y) agonists and candesartan in a non-diabetic model of experimental renal fibrosis is associated with an additive effect. Although lacking in mechanism, this paper has important implications for the potential use of PPAR-Y agonists as antifibrotic therapies in non-diabetic renal disease".

Metabolic syndrome and the development of chronic kidney disease among 118 924 non-diabetic Taiwanese in a retrospective cohort (pages 84–92)

"The relationship between metabolic syndrome and the development of CKD was examined using a large sample of non-diabetics in Taiwan. Metabolic syndrome was significantly related with the development of CKD and amongst metabolic components, central obesity, high blood pressure and high triglycerides were major factors contributing to new-onset CKD".